Evidence map›Paper›PMID 35291295›Full record

ArticlemedRxiv : the preprint server for health sciences2022

Covid-19 Exposure Assessment Tool (CEAT): Easy-to-use tool to quantify exposure based on airflow, group behavior, and infection prevalence in the community.

Brian J Schimmoller, Nídia S Trovão, Molly Isbell, Chirag Goel, Benjamin F Heck, Tenley C Archer, Klint D Cardinal, Neil B Naik, Som Dutta, Ahleah Rohr Daniel and 1 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Brian J SchimmollerSignature Science LLC, Austin, TX, 78759, USA.
Nídia S TrovãoCOVID-19 International Research Team.
Molly IsbellSignature Science LLC, Austin, TX, 78759, USA.
Chirag GoelCOVID-19 International Research Team.
Benjamin F HeckBastion Technologies, NASA Ames Research Center, Moffett Field, CA, 94035, USA.
Tenley C ArcherCOVID-19 International Research Team.
Klint D CardinalLeidos, Inc., NASA Ames Research Center, Moffett Field, CA, 94035, USA.
Neil B NaikLeidos, Inc., NASA Ames Research Center, Moffett Field, CA, 94035, USA.
Som DuttaCOVID-19 International Research Team.
Ahleah Rohr DanielSpace Biosciences Division, NASA Ames Research Center, Moffett Field, CA, 94035, USA.
Afshin BeheshtiCOVID-19 International Research Team.
Ames Research Center · USLeidos (United States) · USSignature Research (United States) · USBroad Institute · USEmergency University · USNational Institutes of Health · USNorthwestern University · USUtah State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 Exposure Assessment Tool (CEAT) allows users to compare respiratory relative risk to SARS-CoV-2 for various scenarios, providing understanding of how combinations of protective measures affect exposure, dose, and risk. CEAT incorporates mechanistic, stochastic and epidemiological factors including the: 1) emission rate of virus, 2) viral aerosol degradation and removal, 3) duration of activity/exposure, 4) inhalation rates, 5) ventilation rates (indoors/outdoors), 6) volume of indoor space, 7) filtration, 8) mask use and effectiveness, 9) distance between people, 10) group size, 11) current infection rates by variant, 12) prevalence of infection and immunity in the community, 13) vaccination rates of the community, and 14) implementation of COVID-19 testing procedures. Demonstration of CEAT, from published studies of COVID-19 transmission events, shows the model accurately predicts transmission. We also show how health and safety professionals at NASA Ames Research Center used CEAT to manage potential risks posed by SARS-CoV-2 exposures. Given its accuracy and flexibility, the wide use of CEAT will have a long lasting beneficial impact in managing both the current COVID-19 pandemic as well as a variety of other scenarios.

Identifiers

PMID35291295
PMCPMC8923112
OpenAlexW4220678176

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.